Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Muscle Invasive Bladder Cancer 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Advanced Metastatic Breast Cancer 1Adenocarcinoma 1

Interventions

pembrolizumab 244Carboplatin 213Pemetrexed 179Cisplatin 133Paclitaxel 115Nivolumab 102Docetaxel 88osimertinib 84durvalumab 79Specimen Handling 56atezolizumab 55Gemcitabine 53Drug Therapy 53Magnetic Resonance Spectroscopy 50Radiosurgery 49Radiotherapy 48Ipilimumab 41130-nm albumin-bound paclitaxel 39cemiplimab 38Bevacizumab 35tislelizumab 31Cetuximab 30amivantamab 23Taxes 22Blood Specimen Collection 21Platinum Compounds 20Immunotherapy 18Immune Checkpoint Inhibitors 18Radiation 17Erlotinib Hydrochloride 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × vistusertib × 1 year × Clear all
NCT02664935 2026-04-28

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

University of Birmingham

Phase 2 Completed
423 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT03334617 2025-10-27

HUDSON

AstraZeneca

Phase 2 Active not recruiting
528 enrolled 16 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡